[Effects of Shengqi Jiangtang Granule on rat model of insulin resistance and its mechanism].
OBJECTIVE
To study the effect of Shengqi Jiangtang Granule (SJG) on rat model of insulin resistance (IR) and explore the mechanism.


METHODS
IR model was induced by high fat diet and peritoneal injection of streptozotocin in Wistar rats. Model rats were randomly divided into the model group, the low, medium and high dose SJG groups treated with corresponding dose of SJG, and thc RGL group with rosiglitazone (RGL). A normal control group was also set up. Blood glucose (BG), protein expression of endothelin-1 (ET-1) and protein kinase C (PKC) in aortic tissue were detected.


RESULTS
BG decreased in the high and medium dose SJG groups and the RGL group after treatment, and the lowest level was shown in the high dose SJG group. Compared with that in the normal group, the expressions of ET-1 and PKC obviously increased in the model group (P<0.05), which was lowered in the RGL group and the high and medium dose SJG groups after treatment in a dosage-depending manner, showing significant difference to those in the model group (P < 0.05).


CONCLUSIONS
SJG can lower blood glucose and inhibit ET-1 and PKC expressions to improve vascular endothelial function, thus to promote insulin sensitiveness and alleviate IR.
Li
Yong
Y
Affiliated Hospital of Medical College of Qindao University, Shandon. liyongsd@yahoo.com.cn
Liu
Meng-Yu
MY
Wang
Yan-Gang
YG
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D019332:Endothelin-1 / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008517:Phytotherapy; D011493:Protein Kinase C / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D004365:Drugs, Chinese Herbal; D019332:Endothelin-1; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C533623:shengqi jiangtang; D000077154:Rosiglitazone; D011493:Protein Kinase C